Bioengineered Nisin Derivative M17Q Has Enhanced Activity against <i>Staphylococcus epidermidis</i>
<i>Staphylococcus epidermidis</i> is frequently implicated in medical device-related infections. As a result of this, novel approaches for control of this opportunistic pathogen are required. We examined the ability of the natural peptide nisin A, produced by <i>Lactococcus lactis&...
Main Authors: | Ellen Twomey, Colin Hill, Des Field, Maire Begley |
---|---|
Format: | Article |
Language: | English |
Published: |
MDPI AG
2020-06-01
|
Series: | Antibiotics |
Subjects: | |
Online Access: | https://www.mdpi.com/2079-6382/9/6/305 |
Similar Items
-
Bioengineered Nisin A Derivatives Display Enhanced Activity against Clinical Neonatal Pathogens
by: Anna Desmond, et al.
Published: (2022-10-01) -
Nisin E Is a Novel Nisin Variant Produced by Multiple <i>Streptococcus equinus</i> Strains
by: Ivan Sugrue, et al.
Published: (2023-02-01) -
Inhibition of Clinical MRSA Isolates by Coagulase Negative Staphylococci of Human Origin
by: Ellen Twomey, et al.
Published: (2024-04-01) -
Synergistic nisin-polymyxin combinations for the control of Pseudomonas biofilm formation
by: Des Field, et al.
Published: (2016-10-01) -
In Silico Prediction and Analysis of Unusual Lantibiotic Resistance Operons in the Genus <i>Corynebacterium</i>
by: Oliver Goldbeck, et al.
Published: (2021-03-01)